Discussion stirs around Seres Therapeutics, Inc. (NASDAQ:MCRB) this week; here is what analysts are saying.

June 16, 2018 - By Migdalia James

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics had 4 analyst reports since January 11, 2018 according to SRatingsIntel. On Tuesday, March 20 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Oppenheimer with “Buy” on Thursday, January 11. As per Thursday, March 8, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) on Thursday, May 10 with “Buy” rating. Below is a list of Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings and price target changes.

10/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0000 Maintain
20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
11/01/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Maintain

The stock decreased 1.28% or $0.11 during the last trading session, reaching $8.5. About 214,843 shares traded or 44.27% up from the average. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 12.75% since June 16, 2017 and is downtrending. It has underperformed by 25.32% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $345.55 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Another recent and important Seres Therapeutics, Inc. (NASDAQ:MCRB) news was published by Investorplace.com which published an article titled: “3 Cheapest Stocks With Greatest Potential for Growth” on May 29, 2018.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.